Natco Pharma on Thursday said it has decided to launch a generic version of Roche’s spinal muscular atrophy (SMA) drug Risdiplam with immediate effect and peg the MRP of the product at ₹15,900.
The pricing is consistent with its stand before the court of law, the Hyderabad-based company said, announcing that the Commercial Appellate Division of the Delhi High Court has dismissed an appeal filed by the Swiss pharma company F. Hoffmann-La Roche AG.
The appeal was preferred against the March 24 order of a Single Judge of the Delhi High Court that paved the way for Natco to launch a generic version of the drug. Spinal Muscular Atrophy is one of the leading causes of death in infants related to the degeneration of neurons. Currently, there are no curative treatment options for SMA, and most of the available options are not financially feasible for Indian patients, Natco Pharma said in a release.
The Single Judge had factored the challenge of invalidity of Roche’s patent and laid special emphasis on the public interest, considering the Swiss company’s pricing had rendered the drug inaccessible and unaffordable to the bulk of its patients, it said.
Natco said it intends to offer some discount to certain deserving patients through its patient access programme.
Published – October 09, 2025 09:17 pm IST
